Clinical Trial Indemnity and Insurance: What CTAs Actually Cover

When a sponsor and an institution sign a Clinical Trial Agreement (CTA), one of the sections most likely to stall negotiation is neither the budget nor the publication clause — it’s the indemnification and insurance language. This is the contractual machinery that decides who actually pays if a trial goes wrong: a participant is injured, a third party sues over the investigational product, or a regulator finds fault with how the trial was conducted. Getting it right matters as much as getting it signed quickly, because it is the provision an institution’s sponsored-programs office, general counsel, and risk-management function will scrutinize hardest before allowing a site to open.

This guide covers what indemnity and insurance provisions are, how sponsors and institutions typically structure them, what a standard CTA indemnification clause does and doesn’t cover, and why this specific section is a recurring, genuine negotiation flashpoint rather than boilerplate.

What “indemnity” and “insurance” mean in a CTA — and why they aren’t the same thing

The two terms get used together so often that they can start to sound like one concept. They aren’t:

• Indemnification is a contractual promise. One party (typically the sponsor) agrees to cover the costs — legal defense, settlements, judgments — that the other party (the institution and its investigators) incurs from claims arising out of the trial. It is a risk-allocation clause; it doesn’t by itself guarantee that money will actually be there when a claim arrives.
• Insurance is the funding mechanism that makes an indemnification promise (or a direct compensation obligation) actually collectible. A sponsor typically evidences this with a clinical trial liability policy and a certificate of insurance; an institution typically relies on its own self-insurance or risk-management program to cover its own exposure.

A CTA that promises broad indemnification but is backed by no verifiable insurance, or an unfunded self-insurance program, is a weaker protection than it looks on paper — which is exactly why an institution’s risk-management office, not just its lawyers, is usually part of the review.

The regulatory anchor: this isn’t just contract custom, it traces to GCP

Sponsor responsibility for trial-related insurance, indemnification, and compensation is not an institutional invention — it’s written directly into the international Good Clinical Practice framework that governs trial conduct:

• ICH E6(R2), Section 5.8 (“Compensation to Subjects and Investigators,” renumbered to Section 3.14 in the finalized ICH E6(R3) guideline, adopted January 2025) states that if required by applicable regulatory requirements, the sponsor should provide insurance or should indemnify the investigator/institution against claims arising from the trial, except for claims that arise from malpractice and/or negligence. The same section directs sponsor policies and procedures to address the costs of treatment of trial subjects for trial-related injuries, in accordance with applicable regulatory requirements.
• That single sentence is the source of the near-universal pattern in CTAs: broad sponsor indemnification of the institution, with an explicit carve-out for the institution’s own negligence or misconduct.
• 45 CFR 46.116 (the US Common Rule’s general requirements for informed consent) requires that, for research involving more than minimal risk, the consent process explain whether compensation and medical treatment are available if injury occurs and, if so, what they consist of — or where further information can be obtained. This is a subject-facing disclosure obligation, distinct from the institution-facing indemnification clause in the CTA, but the two documents have to say consistent things: what the informed consent form promises a participant about injury compensation must match what the CTA actually commits the sponsor to fund.
• Outside the US, the EU Clinical Trials Regulation (EU) No 536/2014, Article 76 takes a related but distinct approach: member states must ensure that systems for compensating trial-related damage are in place “in the form of insurance, a guarantee, or a similar arrangement,” and — recognizing that not every trial adds meaningful risk over standard clinical care — allows a risk-proportionate approach where minimal-risk trials may not require dedicated insurance. Several EU member states have also established national, not-for-profit indemnification mechanisms specifically to help non-commercial sponsors (e.g., investigator-initiated academic trials) meet this obligation without needing to purchase commercial coverage. Because national implementation and minimum coverage expectations vary by member state, a multi-country trial’s insurance arrangements are rarely a single uniform policy.

The regulatory throughline is consistent across these frameworks: the sponsor bears the primary financial responsibility for trial-related risk, but that responsibility is not unconditional — negligence, and generally sovereign or institutional immunity, sit outside it.

Typical structures: sponsor-provided liability insurance vs. institutional self-insurance

In practice, a CTA’s insurance/indemnity section combines two separate coverage tracks that meet at the institution’s door:

Sponsor-provided clinical trial liability insurance

The sponsor (or the CRO acting on its behalf, per its delegated obligations) typically carries a clinical trial liability policy covering the trial’s duration, sized to the trial’s risk profile. Institutions commonly require a certificate of insurance as a condition of activation, naming the institution and often the investigator as an additional insured or confirming the coverage is in force before enrollment can begin. This is the funding source behind both the sponsor’s indemnification promise to the institution and, separately, any direct subject-injury compensation commitment made in the informed consent form.

Institutional self-insurance

Large academic medical centers and university systems frequently self-insure for their own exposures — professional/medical malpractice, general liability, workers’ compensation for employees — rather than purchasing commercial coverage for every category of institutional risk. This self-insurance covers the institution’s own negligence exposure; it is not a substitute for, and does not extend to, the sponsor’s trial-related obligations. The practical effect in a CTA negotiation is that each party is really pointing to a different funding source: the sponsor’s commercial policy backs its indemnification of the institution, and the institution’s self-insurance program backs the (usually narrower) indemnification it offers back to the sponsor for its own negligence.

Minimum coverage amounts are set by institutional risk-management policy and negotiated per trial or per master agreement — they vary by trial phase, therapeutic area, and jurisdiction, so there is no single figure that applies as a universal norm across CTAs; a sponsored-programs office typically has its own institutional minimum it will not go below, and a sponsor’s insurer typically has its own standard limits it offers by default.

What the indemnification clause typically covers

The core sponsor-to-institution indemnification obligation in a CTA is usually written broadly, to cover claims, demands, losses, and judgments arising from:

• The investigational product itself, including its known and unknown effects;
• The protocol’s design, including any claim that a design defect caused a participant’s injury;
• The sponsor’s own acts, omissions, or negligence in performing its obligations under the CTA; and
• The institution’s and investigators’ proper performance of the study strictly in accordance with the protocol and the sponsor’s written instructions.

A well-drafted clause also extends to a sponsor’s downstream use of the results the institution generates — not just the conduct of the study itself — since a claim can arise later, from how a sponsor uses the trial’s findings, rather than from anything that happened at the site.

What it typically carves out — and why that carve-out is the real negotiation point

Sponsor indemnification is essentially never unconditional. The standard, expected carve-outs remove coverage for claims arising from:

• Institutional or investigator negligence — the institution’s own failure to exercise reasonable care in conducting the trial;
• Willful misconduct by an employee, agent, or officer of the institution;
• Material non-compliance with the protocol — a negligent failure to substantially follow the approved protocol or applicable regulatory requirements; and
• IRB/ethics-committee non-compliance — conducting the study outside the terms of the institutional review board’s approval.

This mirrors ICH E6’s own “except for claims arising from malpractice and/or negligence” language almost exactly, which is why sponsors treat it as a floor they won’t negotiate below. Where negotiation actually happens is at the margins of that floor:

• How broadly “negligence” is defined — a sponsor’s initial draft may define the carve-out broadly enough to capture routine, low-severity site errors that shouldn’t reasonably void the entire indemnification obligation for an otherwise-covered claim; institutions typically push to narrow this to conduct that actually caused the injury.
• Whether non-compliance has to actually cause the harm — institutional counsel typically insists that a technical or immaterial protocol deviation that didn’t contribute to the injury shouldn’t strip indemnification entirely; a sponsor’s initial draft may not make that causal link explicit.
• Mutual vs. one-directional indemnification — most CTAs end up bilateral: the sponsor indemnifies the institution for the categories above, and the institution separately, and typically much more narrowly, indemnifies the sponsor for claims arising from the institution’s own negligence or misconduct. The scope and caps on each direction rarely match, and reconciling that asymmetry is routine negotiation work.
• Sovereign immunity and public-institution limits — a significant number of US public universities and state-affiliated academic medical centers are statutorily barred from indemnifying a third party at all, because state constitutions or tort-claims statutes restrict the disbursement of public funds and preserve sovereign immunity from suit. The University of Texas System’s own public guidance on this point is explicit that state law prevents it from indemnifying a sponsor, even though sponsors routinely ask for reciprocal indemnification as a matter of course. This creates a structural mismatch — a sponsor wants mutual protection, a state institution frequently cannot legally provide it — that a sponsored-programs office has to resolve early, often by substituting language that acknowledges the institution’s liability under its own state tort-claims act (with its statutory damages cap) instead of a contractual indemnity promise.
• The relationship to subject-injury compensation language — the CTA’s indemnification clause protects the institution; a separate subject-injury provision (echoed in the informed consent form per 45 CFR 46.116 above) addresses what happens for the participant directly, typically medical costs for a trial-related injury, without the participant having to prove negligence first. Reviewers checking a CTA need to confirm these two provisions are consistent with each other and with the consent language a participant will actually read — a mismatch between what the ICF promises and what the CTA actually funds is a real, avoidable compliance gap.

Why sponsored-programs and legal offices treat this as a serious review item

Indemnification and insurance provisions get flagged for careful legal and risk-management review, not just a signature, for a few concrete reasons:

• The institution is agreeing to accept legal exposure on behalf of investigators, staff, and — indirectly — participants, often years before any claim would actually be filed (many CTAs specify a survival period for indemnification obligations well beyond the study’s closeout).
• Public institutions have to reconcile what a sponsor’s standard template assumes (mutual, unconditional indemnification) against what state law actually permits them to promise.
• The clause has to stay consistent with what the informed consent form tells participants, and with the institution’s own IRB-approved subject-injury language — three documents (CTA, ICF, IRB protocol) that all need to agree with each other.
• Verifying the sponsor’s insurance is real and adequate — not just promised — is an operational step (collecting and checking a current certificate of insurance) that has to happen before the site can activate, not after.

None of this is unique to any one sponsor or institution — it’s the same structural tension in essentially every CTA: a sponsor wants predictable, capped exposure and a site wants to be made whole for anything genuinely outside its control, and the indemnification clause is where those two positions actually get reconciled in writing.

Frequently asked questions

Does ICH E6 require a sponsor to carry insurance?

ICH E6(R2) Section 5.8 (E6(R3) Section 3.14) says the sponsor should provide insurance or indemnify the investigator/institution “if required by the applicable regulatory requirement(s)” — GCP itself sets the principle, but the binding insurance mandate, and any minimum coverage level, comes from the national or regional regulation that actually applies to the trial (for example, the EU Clinical Trials Regulation’s Article 76 in the EU, or the institution’s own policy in jurisdictions with no statutory minimum).

Is subject-injury compensation the same thing as institutional indemnification?

No. Subject-injury language addresses what a participant is owed (typically medical treatment costs for a trial-related injury) if something goes wrong, usually without requiring the participant to prove fault. Indemnification addresses what the sponsor owes the institution and its investigators if a third party — which can include the participant — brings a claim. They’re related and need to be consistent, but they protect different parties and are often documented in different places (the informed consent form vs. the CTA).

Can a public university indemnify a pharmaceutical sponsor?

Often not, or only in a limited form. Many US state universities and state-affiliated academic medical centers are barred by sovereign-immunity doctrine and state constitutional or statutory restrictions on the disbursement of public funds from providing contractual indemnification to a third party. These institutions typically offer instead to acknowledge liability under their state’s tort claims act, which usually carries a statutory damages cap, rather than an open-ended contractual indemnity.

Why does the sponsor’s indemnification exclude institutional negligence?

Because the underlying GCP principle (ICH E6 Section 5.8/3.14) and standard institutional risk-management practice both treat “negligence” as the party’s own responsibility to insure against, not something the other party should have to fund. A sponsor is willing to stand behind the investigational product, the protocol design, and its own conduct — but not behind a site’s own failure to follow the protocol or exercise reasonable care.

Who reviews the indemnification and insurance clause at an institution?

Typically the sponsored-programs or clinical trials office coordinates the review with institutional legal counsel and, for the insurance-adequacy question specifically, risk management. Larger academic medical centers often have standard fallback language (like the University of Texas System’s published indemnification checklist and sample clauses) that streamlines routine reviews and flags which sponsor-drafted terms need escalation.

Related CASRAI resources

For the document this clause lives inside, see the sponsored research agreement term and the guide on industry-university research partnership agreement structures. For the sponsor’s own GCP obligations that this section of the CTA implements, see Good Clinical Practice (GCP) certification and the Contract Research Organization (CRO) term for how these obligations transfer when a sponsor delegates trial conduct. For the participant-facing side of trial-related costs, see Clinical Trial Participant Payments. For broader trial administration and definitions, see What Is a Clinical Trial? and the Clinical Research Administration pillar page.